Cargando…
Disease progression in patients with single, large-scale mitochondrial DNA deletions
Single, large-scale deletions of mitochondrial DNA are a common cause of mitochondrial disease and cause a broad phenotypic spectrum ranging from mild myopathy to devastating multi-system syndromes such as Kearns-Sayre syndrome. Studies to date have been inconsistent on the value of putative predict...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914470/ https://www.ncbi.nlm.nih.gov/pubmed/24277717 http://dx.doi.org/10.1093/brain/awt321 |
_version_ | 1782302411163959296 |
---|---|
author | Grady, John P. Campbell, Georgia Ratnaike, Thiloka Blakely, Emma L. Falkous, Gavin Nesbitt, Victoria Schaefer, Andrew M. McNally, Richard J. Gorman, Grainne S. Taylor, Robert W. Turnbull, Doug M. McFarland, Robert |
author_facet | Grady, John P. Campbell, Georgia Ratnaike, Thiloka Blakely, Emma L. Falkous, Gavin Nesbitt, Victoria Schaefer, Andrew M. McNally, Richard J. Gorman, Grainne S. Taylor, Robert W. Turnbull, Doug M. McFarland, Robert |
author_sort | Grady, John P. |
collection | PubMed |
description | Single, large-scale deletions of mitochondrial DNA are a common cause of mitochondrial disease and cause a broad phenotypic spectrum ranging from mild myopathy to devastating multi-system syndromes such as Kearns-Sayre syndrome. Studies to date have been inconsistent on the value of putative predictors of clinical phenotype and disease progression such as mutation load and the size or location of the deletion. Using a cohort of 87 patients with single, large-scale mitochondrial DNA deletions we demonstrate that a variety of outcome measures such as COX-deficient fibre density, age-at-onset of symptoms and progression of disease burden, as measured by the Newcastle Mitochondrial Disease Adult Scale, are significantly (P < 0.05) correlated with the size of the deletion, the deletion heteroplasmy level in skeletal muscle, and the location of the deletion within the genome. We validate these findings with re-analysis of 256 cases from published data and clarify the previously conflicting information of the value of these predictors, identifying that multiple regression analysis is necessary to understand the effect of these interrelated predictors. Furthermore, we have used mixed modelling techniques to model the progression of disease according to these predictors, allowing a better understanding of the progression over time of this strikingly variable disease. In this way we have developed a new paradigm in clinical mitochondrial disease assessment and management that sidesteps the perennial difficulty of ascribing a discrete clinical phenotype to a broad multi-dimensional and progressive spectrum of disease, establishing a framework to allow better understanding of disease progression. |
format | Online Article Text |
id | pubmed-3914470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39144702014-02-05 Disease progression in patients with single, large-scale mitochondrial DNA deletions Grady, John P. Campbell, Georgia Ratnaike, Thiloka Blakely, Emma L. Falkous, Gavin Nesbitt, Victoria Schaefer, Andrew M. McNally, Richard J. Gorman, Grainne S. Taylor, Robert W. Turnbull, Doug M. McFarland, Robert Brain Original Articles Single, large-scale deletions of mitochondrial DNA are a common cause of mitochondrial disease and cause a broad phenotypic spectrum ranging from mild myopathy to devastating multi-system syndromes such as Kearns-Sayre syndrome. Studies to date have been inconsistent on the value of putative predictors of clinical phenotype and disease progression such as mutation load and the size or location of the deletion. Using a cohort of 87 patients with single, large-scale mitochondrial DNA deletions we demonstrate that a variety of outcome measures such as COX-deficient fibre density, age-at-onset of symptoms and progression of disease burden, as measured by the Newcastle Mitochondrial Disease Adult Scale, are significantly (P < 0.05) correlated with the size of the deletion, the deletion heteroplasmy level in skeletal muscle, and the location of the deletion within the genome. We validate these findings with re-analysis of 256 cases from published data and clarify the previously conflicting information of the value of these predictors, identifying that multiple regression analysis is necessary to understand the effect of these interrelated predictors. Furthermore, we have used mixed modelling techniques to model the progression of disease according to these predictors, allowing a better understanding of the progression over time of this strikingly variable disease. In this way we have developed a new paradigm in clinical mitochondrial disease assessment and management that sidesteps the perennial difficulty of ascribing a discrete clinical phenotype to a broad multi-dimensional and progressive spectrum of disease, establishing a framework to allow better understanding of disease progression. Oxford University Press 2014-02 2013-11-23 /pmc/articles/PMC3914470/ /pubmed/24277717 http://dx.doi.org/10.1093/brain/awt321 Text en © The Author (2013). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Grady, John P. Campbell, Georgia Ratnaike, Thiloka Blakely, Emma L. Falkous, Gavin Nesbitt, Victoria Schaefer, Andrew M. McNally, Richard J. Gorman, Grainne S. Taylor, Robert W. Turnbull, Doug M. McFarland, Robert Disease progression in patients with single, large-scale mitochondrial DNA deletions |
title | Disease progression in patients with single, large-scale mitochondrial DNA deletions |
title_full | Disease progression in patients with single, large-scale mitochondrial DNA deletions |
title_fullStr | Disease progression in patients with single, large-scale mitochondrial DNA deletions |
title_full_unstemmed | Disease progression in patients with single, large-scale mitochondrial DNA deletions |
title_short | Disease progression in patients with single, large-scale mitochondrial DNA deletions |
title_sort | disease progression in patients with single, large-scale mitochondrial dna deletions |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914470/ https://www.ncbi.nlm.nih.gov/pubmed/24277717 http://dx.doi.org/10.1093/brain/awt321 |
work_keys_str_mv | AT gradyjohnp diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT campbellgeorgia diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT ratnaikethiloka diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT blakelyemmal diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT falkousgavin diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT nesbittvictoria diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT schaeferandrewm diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT mcnallyrichardj diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT gormangrainnes diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT taylorrobertw diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT turnbulldougm diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions AT mcfarlandrobert diseaseprogressioninpatientswithsinglelargescalemitochondrialdnadeletions |